title: [Auxiliary hepatic transplantation in iproniazid-induced subfulminant hepatitis. Should iproniazid still be sold in France?].
abstract: We report a new case of subfulminant hepatitis due to iproniazid, a MAO-inhibitor antidepressant, in a 27-year-old man. An auxiliary liver transplantation was performed. Liver function returned to normal and the patient was discharged from the hospital. However, the patient's native liver did not regenerate, and immunosuppressive therapy had to be maintained. Iproniazid hepatotoxicity is characterized by jaundice in 1% of cases, with a fulminant or subfulminant course in 20% of icteric patients. Although iproniazid is no longer sold in most countries, it is still commercialized in France. Because of the frequency and severity of hepatic injury, commercialization of iproniazid in France should no longer be authorized.
authors.affiliation: Service d'Hépatologie et de Gastroentérologie, Cytologie Pathologiques, Hôpital Henri-Mondor, Créteil.
authors.forename: F
authors.initials: F
authors.lastname: Maille
authors.forename: C
authors.initials: C
authors.lastname: Duvoux
authors.forename: D
authors.initials: D
authors.lastname: Cherqui
authors.forename: C
authors.initials: C
authors.lastname: Radier
authors.forename: E S
authors.initials: ES
authors.lastname: Zafrani
authors.forename: D
authors.initials: D
authors.lastname: Dhumeaux
mesh_terms: D000328:Adult; D000928:Antidepressive Agents / Q000009:adverse effects*; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology* / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007490:Iproniazid / Q000009:adverse effects*; D016031:Liver Transplantation; D008297:Male; D008996:Monoamine Oxidase Inhibitors / Q000009:adverse effects*; D013997:Time Factors
chemical_list: D000928:Antidepressive Agents; D007166:Immunosuppressive Agents; D008996:Monoamine Oxidase Inhibitors; D007490:Iproniazid
vernacular_title: Transplantation hépatique auxiliaire pour hépatite subfulminante à l'iproniazide. Doit-on maintenir la commercialisation de l'iproniazide en France?